– USA, CA – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the election of Frank Stokes to its Board as an additional independent Director effective on June 17, 2021.
“We are excited to welcome Mr. Frank Stokes to our dedicated Board of Directors,” said CEO, Ron Rocca. “Frank brings tremendous capabilities as both a former investment banker and a current CFO for a public skin care diagnostic company. His multifaceted experience and knowledge in the advanced diagnostics and life sciences industry will be valuable for the next phase of Exagen’s growth.”
Mr. Stokes will also serve as Chair of the Audit Committee.
About Franck Stokes
Mr. Stokes has served as the CFO of Castle Biosciences, Inc., a skin cancer diagnostics company, since December 2017. From January 2017 to December 2017, Mr. Stokes served as CFO of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann. Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools, and diagnostics sector investment banking efforts and managed financings and mergers and acquisitions transactions.
“I am honored to join the board of an innovative company with a successful track record and reputation for enabling providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases,” said Mr. Stokes. “Exagen offers a highly valuable testing portfolio. I look forward to working with the executive leadership team and board of directors, as the Company continues to execute on its compelling mission and growth strategy.”
Mr. Stokes obtained a Bachelor of Science in Business Administration, Master of Business Administration, and Doctor of Jurisprudence, all from the University of North Carolina at Chapel Hill.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.
For more information: https://exagen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.